FDA Approves Rapiblyk for Atrial Fibrillation and Atrial Flutter in the Critical Care Setting
AOP Orphan Pharmaceuticals GmbH announced that the U.S. Food and Drug Administration (FDA) has granted regulatory approval for Rapiblyk (landiolol) in the hospital critical care setting for the treatment of the severe heart condition, supraventricular tachycardia. The approval is based on clinical studies which demonstrated that Rapiblyk (landiolol) enables rapid management of the heart rate with minimal reduction of blood pressure.
- Rapiblyk approval in the U.S. represents an important milestone for patients experiencing supraventricular tachycardia, including atrial fibrillation and atrial flutter, who need rapid and short-term heart rate reduction. The approval will provide patients in the U.S. with a new treatment option.
Source: AOP Orphan Pharmaceuticals GmbH
